The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses
Abstract
:1. Introduction
- 1.
- Immunology and vaccinology
- Incomplete recovery of memory T cells after SVR, which allows re-infection of HCV in successfully treated subjects.
- Significance of both broadly neutralizing antibodies and T cells in HCV-specific immune responses, which is important for prophylactic HCV vaccine development.
- Suggestion for controlled human infection models in HCV vaccine trials.
- 2.
- Virology and virus-host interaction
- Persistence of epigenetic changes in the liver, even after SVR, which may lead to the development of HCC.
- Altered lipid metabolism during the HCV life cycle in infected hepatocytes.
- 3.
- Clinical issues and public health
- Issues in difficult-to-cure patients/viruses (genotype 3 and unusual subtypes).
- Enhanced HCV testing and linkage to care.
- Importance of rapid diagnostic tests.
2. Hepatocellular Carcinoma, Cirrhosis, and Pathogenesis
3. Viral Entry and Replication
4. Viral Assembly and Virus–Host Interaction
5. Innate and Adaptive Immune Responses
6. Emerging and Related Viruses
7. Vaccines and New Antiviral Agents
8. Enteric Hepatitis Viruses
9. Issues in DAA Treatment
10. HCV: 30 Years and Future
Author Contributions
Funding
Conflicts of Interest
References
- Spearman, C.W.; Dusheiko, G.M.; Hellard, M.; Sonderup, M. Hepatitis C. Lancet 2019, 394, 1451–1466. [Google Scholar] [CrossRef]
- Rasche, A.; Sander, A.L.; Corman, V.M.; Drexler, J.F. Evolutionary biology of human hepatitis viruses. J. Hepatol. 2019, 70, 501–520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ninio, L.; Nissani, A.; Meirson, T.; Domovitz, T.; Genna, A.; Twafra, S.; Srikanth, K.D.; Dabour, R.; Avraham, E.; Davidovich, A.; et al. Hepatitis C virus enhances the invasiveness of hepatocellular carcinoma via EGFR-mediated invadopodia formation and activation. Cells 2019, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hamdane, N.; Juhling, F.; Crouchet, E.; El Saghire, H.; Thumann, C.; Oudot, M.A.; Bandiera, S.; Saviano, A.; Ponsolles, C.; Roca Suarez, A.A.; et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology 2019, 156, 2313–2329.e2317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prentoe, J.; Velazquez-Moctezuma, R.; Augestad, E.H.; Galli, A.; Wang, R.; Law, M.; Alter, H.; Bukh, J. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. Proc. Natl. Acad. Sci. USA 2019, 116, 10039–10047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalemera, M.; Mincheva, D.; Grove, J.; Illingworth, C.J.R. Building a mechanistic mathematical model of hepatitis C virus entry. PLoS Comput. Biol. 2019, 15, e1006905. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Costa, R.; Todt, D.; Zapatero-Belinchon, F.; Schenk, C.; Anastasiou, O.E.; Walker, A.; Hertel, B.; Timmer, L.; Bojkova, D.; Ruckert, M.; et al. SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. J. Hepatol. 2019, 70, 603–614. [Google Scholar] [CrossRef] [PubMed]
- Kitab, B.; Satoh, M.; Ohmori, Y.; Munakata, T.; Sudoh, M.; Kohara, M.; Tsukiyama-Kohara, K. Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation. J. Biol. Chem. 2019, 294, 5759–5773. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lassen, S.; Gruttner, C.; Nguyen-Dinh, V.; Herker, E. Perilipin-2 is critical for efficient lipoprotein and hepatitis C virus particle production. J. Cell Sci. 2019, 132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gerresheim, G.K.; Roeb, E.; Michel, A.M.; Niepmann, M. Hepatitis C virus downregulates core subunits of oxidative phosphorylation, reminiscent of the Warburg effect in cancer cells. Cells 2019, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nguyen, L.P.; Tran, S.C.; Suetsugu, S.; Lim, Y.S.; Hwang, S.B. PACSIN2 interacts with nonstructural 5A protein and regulates hepatitis C virus assembly. J. Virol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Han, J.W.; Sung, P.S.; Kim, K.H.; Hong, S.H.; Shin, E.C.; Jun Song, M.; Park, S.H. Dynamic changes in ex vivo T-cell function after viral clearance in chronic HCV infection. J. Infect. Dis. 2019, 220, 1290–1301. [Google Scholar] [CrossRef] [PubMed]
- Walker, C.M. Adaptive immune responses in hepatitis A virus and hepatitis E virus infections. Cold Spring Harb Perspect Med. 2019, 9. [Google Scholar] [CrossRef] [PubMed]
- Belkaya, S.; Michailidis, E.; Korol, C.B.; Kabbani, M.; Cobat, A.; Bastard, P.; Lee, Y.S.; Hernandez, N.; Drutman, S.; de Jong, Y.P.; et al. Inherited IL-18BP deficiency in human fulminant viral hepatitis. J. Exp. Med. 2019, 216, 1777–1790. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Chang, D.Y.; Lee, H.W.; Lee, H.; Kim, J.H.; Sung, P.S.; Kim, K.H.; Hong, S.H.; Kang, W.; Lee, J.; et al. Innate-like cytotoxic function of bystander-activated CD8(+) T cells is associated with liver injury in acute hepatitis A. Immunity 2018, 48, 161–173.e165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gambato, M.; Canini, L.; Lens, S.; Graw, F.; Perpinan, E.; Londono, M.C.; Uprichard, S.L.; Marino, Z.; Reverter, E.; Bartres, C.; et al. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver Int. 2019, 39, 826–834. [Google Scholar] [CrossRef] [PubMed]
- Dahari, H.; Canini, L.; Graw, F.; Uprichard, S.L.; Araujo, E.S.; Penaranda, G.; Coquet, E.; Chiche, L.; Riso, A.; Renou, C.; et al. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. J. Hepatol. 2016, 64, 1232–1239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Canini, L.; Imamura, M.; Kawakami, Y.; Uprichard, S.L.; Cotler, S.J.; Dahari, H.; Chayama, K. HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. PLoS ONE 2017, 12, e0187409. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shin, E.-C.; Han, J.W.; Kang, W.; Kato, T.; Kim, S.-J.; Zhong, J.; Kim, S.; Park, S.-H.; Sung, P.S.; Watashi, K.; et al. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses. Viruses 2020, 12, 302. https://doi.org/10.3390/v12030302
Shin E-C, Han JW, Kang W, Kato T, Kim S-J, Zhong J, Kim S, Park S-H, Sung PS, Watashi K, et al. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses. Viruses. 2020; 12(3):302. https://doi.org/10.3390/v12030302
Chicago/Turabian StyleShin, Eui-Cheol, Ji Won Han, Wonseok Kang, Takanobu Kato, Seong-Jun Kim, Jin Zhong, Seungtaek Kim, Su-Hyung Park, Pil Soo Sung, Koichi Watashi, and et al. 2020. "The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses" Viruses 12, no. 3: 302. https://doi.org/10.3390/v12030302
APA StyleShin, E.-C., Han, J. W., Kang, W., Kato, T., Kim, S.-J., Zhong, J., Kim, S., Park, S.-H., Sung, P. S., Watashi, K., Park, J. Y., Windisch, M. P., Oh, J.-W., Wakita, T., Han, K.-H., & Jang, S. K. (2020). The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses. Viruses, 12(3), 302. https://doi.org/10.3390/v12030302